Research Reports on Biotech Equities -- Galena Biopharma, Mast Therapeutics, Medivation, and Amgen

NEW YORK, September 16, 2016 /PRNewswire/ --

The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration

Galena Biopharma  

San Ramon, California-based Galena Biopharma Inc.'s shares gained 0.82%, closing Thursday's trading session at $0.33. The stock recorded a trading volume of 4.21 million shares. Shares of the Company are trading 22.52% below their 50-day moving average. Additionally, shares of Galena Biopharma, which focuses on developing and commercializing oncology therapeutics that address major unmet medical needs, have a Relative Strength Index (RSI) of 33.40.

On September 12^th, 2016, Galena Biopharma announced the issuance of a second Japanese Patent containing composition and method of use claims for GALE-401, the Company's controlled release version of anagrelide. The patent covers the treatment of patients suffering from myeloproliferative diseases, including myeloproliferative neoplasms such as essential thrombocythemia and polycythemia vera.  The patent provides GALE-401 exclusivity until 2029, not including any patent term extensions. Free research report on GALE is available at: http://stock-callers.com/registration/?symbol=GALE

Mast Therapeutics  

On Thursday, shares in San Diego, California headquartered Mast Therapeutics Inc. recorded a trading volume of 7.58 million shares, which was above their three months average volume of 4.21 million shares. The stock edged 15.20% higher, ending the day at $0.57. The Company's shares have surged 35.69% in the last month, 32.53% in the previous three months, and 35.69% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 31.10% and 52.51%, respectively. Furthermore, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have an RSI of 59.82.

On September 6^th, 2016, Mast Therapeutics announced that it is joining other industry leaders, patient advocacy groups, researchers, clinicians, policymakers, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research both in the US and globally. SCD is an inherited, lifelong disorder characterized by red blood cells that become rigid and sickle-shaped, which causes them to stick together and block the flow of oxygen to the body, leading to intense pain and other serious issues such as stroke, organ failure, and death. SCD affects approximately 100,000 Americans and millions worldwide. The complimentary research report on MSTX can be downloaded at: http://stock-callers.com/registration/?symbol=MSTX

Medivation  

San Francisco, California headquartered Medivation Inc.'s stock finished the day 0.09% lower at $81.05. A total volume of 5.64 million shares was traded, which was above their three months average volume of 3.82 million shares. The Company's shares have gained 24.27% in the last one month, 36.54% in the previous three months, and 67.67% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 16.94% and 55.19%, respectively. Additionally, shares of Medivation, which focuses on the development and commercialization of medical therapies to treat serious diseases in the US, have an RSI of 87.68.

On August 22^nd, 2016, Pfizer Inc. and Medivation announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger.

On August 23^rd, 2016, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold'. Visit us today and access our complete research report on MDVN at: http://stock-callers.com/registration/?symbol=MDVN

Amgen 

Shares in Thousand Oaks, California headquartered Amgen Inc. ended yesterday's session 1.47% higher at $172.64. The stock recorded a trading volume of 2.92 million shares. The Company's shares have advanced 0.28% in the last one month, 14.01% over the previous three months, and 8.42% on an YTD basis. The stock is trading 2.45% above its 50-day moving average and 10.87% above its 200-day moving average. Moreover, shares of Amgen, which engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide, have an RSI of 56.76.

On August 26^th, 2016, research firm Gabelli & Co. initiated a 'Hold' rating on the Company's stock.

On September 15^th, 2016, Amgen announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. In an analysis of exploratory endpoints, both doses of erenumab were associated with significant improvements in health-related quality of life, headache impact, disability, and level of pain interference, compared to placebo. Get free access to your research report on AMGN at: http://stock-callers.com/registration/?symbol=AMGN

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA